Skip to content
Screener

Vericel VCEL Total Revenue

Total Revenue at other companies

Stryker logo
StrykerSYK
$6.59B+9.4%
CONMED logo
CONMEDCNMD
$343.49M+0.3%
Anika Therapeutics logo
Anika TherapeuticsANIK
$32.61M+15.6%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$2.18B+4.8%
LeMaitre Vascular logo
LeMaitre VascularLMAT
$70.38M+9.6%
MiMedx Group logo
MiMedx GroupMDXG
$64.36M-34.7%

Segments

By product

See full
M A C I Implants and kits$65.51M+22.5%
MACI implants, kits, and instruments$49.89M+26.5%
Epicel$10.4M+20.8%
Biopsy kits$614K-4.4%

Other financials

Income statement

See full
Gross profit$56.4M+21.0%
Operating income$434.0K+121%
Net income$2.2M+499%
EPS (diluted)$0.04+500%

Balance sheet

See full
Cash & equivalents$125.4M+55.7%
Total debt$93.1M-7.3%
Total equity$370.0M+20.6%
Total assets$502.9M+15.4%

Cash flow

See full
Operating cash flow$16.2M+97.1%
CapEx$1.9M-76.2%
Free cash flow$14.3M+17,504%

Valuation

See full
Market cap$2.31B+29.1%
Enterprise value$2.28B+25.9%
P/E95.3×-156×
P/S7.5×+0.4×

Profitability

See full
Gross margin74.6%+1.1pp
Operating margin6%+5.5pp
Net margin7.9%+5.1pp
FCF margin20.1%

Returns & leverage

See full
Return on equity7.2%+4.6pp
Debt / equity0.3×-0.1×
Current ratio+0.1×

Where this comes from

Reported directly by Vericel in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Vericel’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 8:49 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-050836
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Product sales, net$77,457$63,240$145,882$115,838
Total revenue77,45763,240145,882115,838
Cost of product sales21,05516,62740,21432,952
Gross profit56,40246,613105,66882,886
Research and development7,4936,73115,59713,992
Selling, general and administrative48,47541,91197,70183,715
Total operating expenses55,96848,642113,29897,707
Income (loss) from operations434(2,029)(7,630)(14,821)

Item 1. Financial Statements (Unaudited)

FAQ

What is Vericel's total revenue?
Vericel (VCEL) reported total revenue of $77.46M in Q2 2026.
How has Vericel's total revenue changed year-over-year?
Vericel's total revenue increased by 22.5% year-over-year, from $63.24M to $77.46M.
What is the long-term trend for Vericel's total revenue?
Over 4 years (2021 to 2025), Vericel's total revenue has grown at a 15.3% compound annual growth rate (CAGR), from $156.18M to $276.26M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Vericel's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude